Abstract
Objectives Neutrophil elastase (NE) plays an important role in the pathogenesis of acute respiratory distress syndrome (ARDS). Sivelestat sodium, an NE inhibitor, has been approved in Japan for the treatment of patients with ARDS combined with systemic inflammatory response syndrome (SIRS). This trial was designed to evaluate the role of sivelestat sodium in mild-to-moderate ARDS combined with SIRS.
Methods We conducted a multicentre, double-blind, randomized, placebo-controlled trial enrolling patients diagnosed with mild-to-moderate ARDS combined with SIRS admitted within 72 hours of ARDS onset (clinicaltrials.gov, NCT04909697). Patients were randomized in a 1:1 fashion to sivelestat or placebo. Trial drugs were administrated as a 24-hour continuous intravenous infusion at a rate of 0.2 mg/kg/h for 5 days. The primary outcome was PaO2/FiO2 ratio change on day 3 after randomization, which was defined as (PaO2/FiO2 ratio on day 3 – baseline PaO2/FiO2 ratio)/baseline PaO2/FiO2 ratio.
Results The study was stopped early at the recommendation of an independent Data and Safety Monitoring Board, which noted a between-group difference in mortality. A total of 162 patients were randomized, of whom 81 were assigned to receive sivelestat sodium and 81 placebo. On day 3, the PaO2/FiO2 ratio improved by 36% in the sivelestat group compared to 3% in the placebo group (difference, 0.27; 95% CI, 0.13 to 0.41, p < 0.001). In addition, The invasive mechanical ventilation-free days within 28 days was significantly longer in the sivelestat sodium group compared to the placebo group (median 26.9 days vs. 21.0 days, p = 0.004). The Kaplan-Meier curves showed a significant reduction in 90-day mortality in patients receiving sivelestat compared to those not receiving sivelestat (hazard ratio, 0.51; 95% CI, 0.26 to 0.99; log-rank p = 0.044).
Conclusion In patients with mild-to-moderate ARDS combined with SIRS, sivelestat sodium may improve oxygenation on day3, increase invasive mechanical ventilation-free days, and was associated with improved survival.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04909697
Funding Statement
This study was funded by Shanghai Huilun (Jiangsu) Pharmaceutical Co., Ltd., which is also responsible for the supply of the study drug andplacebo as well as distribution to the participating centers. Funding agencyhad no input into the design, conduct, data collection, statistical analysis, orwriting of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
(1)Ethics committee of sichuan people's hospital gave ethical approval for this work. (2)Ethics committee of affiliated hospital of chengdu university of traditional chinese medicine gave ethical approval for this work. (3)Ethics committee of chengdu shuangliu district first people's hospital gave ethical approval for this work. (4)Ethics committee of chengdu second people's hospital gave ethical approval for this work. (5)Ethics committee of chengdu fifth people's hospital gave ethical approval for this work. (6)Ethics committee of affiliated hospital of chengdu university gave ethical approval for this work. (7)Ethics committee of chengdu third people's hospital gave ethical approval for this work. (8)Ethics committee of sichuan cancer hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
We reviewed the project data again and made a detailed evaluation of the project data. Subsequently, the statistical analysis was re-conducted and the updated data results were shown in Table 2.
Data Availability
All data produced in the present study are available upon reasonable request to the authors. And all data produced in the present work are contained in the manuscript.
